CD19-Targeted Chimeric Antigen Receptor (CAR)-Modified T Cell Immunotherapy For Adult B Cell Malignancies

Cameron J. Turtle, MD, PhD, covers the background and rationale for CD19 CAR-T cell therapy, clinical responses and approaches to mitigate toxicity.